[Quali-quantitative study of the social variables defining transmission scenarios of Argentine Hemorrhagic Fever in the provinces of Buenos Aires and Santa Fe, 2001-2010]. / Estudio cualicuantitativo de las variables sociales que definen escenarios de transmisión de la fiebre hemorrágica argentina en las provincias de Buenos Aires y Santa Fe, 2001-2010.

The aim of this paper was to characterize transmission scenarios of Argentine Hemorrhagic Fever in the post-vaccination period (2001-2010). The study was made up of three phases. The first consisted of a quantitative analysis using the database of the Dr. Julio I. Maiztegui National Institute of Human Viral Diseases [Instituto Nacional de Enfermedades Virales Humanas] regarding the confirmed cases in the period of study (221 cases). Taking into account the transmission site and the known endemic area, cases were grouped into three hypothetical transmission scenarios, identified as: a) classical, b) emerging-reemerging, c) traveling. In the second phase, in order to test these hypotheses, in-depth interviews were carried out from August to September 2011 within an intentionally selected sample of patients distributed proportionally among the three hypotheses. Finally, in the third stage, the data obtained for each hypothetical scenario were grouped into three spatiotemporal scales: the microscale (subject), the mesoscale (locality) and macroscale (region). The results show that new transmission sites are associated with the social dynamics of cereal production and port-bound routes.

Estudio cualicuantitativo de las variables sociales que definen escenarios de transmisión de la fiebre hemorrágica argentina en las provincias de Buenos Aires y Santa Fe, 2001-2010 / Quali-quantitative study of the social variables defining transmission scenarios of Argentine Hemorrhagic Fever in the provinces of Buenos Aires and Santa Fe, 2001-2010

El objetivo de este artículo es caracterizar los escenarios de transmisión de fiebre hemorrágica argentina (FHA) en el período de vacunación (2001-2010). El estudio constó de tres etapas. En la primera, se realizó un análisis cuantitativo de la base de datos del Instituto Nacional de Enfermedades Virales Humanas "Dr. Julio I. Maiztegui" (INEVH) de casos de FHA confirmados en el período (221 casos) que, sobre la base del lugar de transmisión y la zona endémica conocida, se agruparon según tres hipótesis de escenario: clásico, emergente-reemergente, y viajero. En la segunda etapa, para poner a prueba las hipótesis, se realizaron entrevistas en campo, entre agosto y octubre de 2011, a una muestra de selección intencional de pacientes distribuida proporcionalmente entre las tres hipótesis. Finalmente, en una tercera etapa, los datos generados para cada hipótesis de escenario se agruparon en tres escalas espacio-temporales: microescala (sujeto), mesoescala (localidad) y macroescala (región). Los resultados muestran que los nuevos lugares de transmisión estarían asociados a las dinámicas socioproductivas del cereal y las rutas al puerto.

.

Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.

As a consequence of YF outbreaks that hit Brazil, Argentina, and Paraguay in 2008-2009, a significant demand for YF vaccination was subsequently observed in Argentina, a country where the usual vaccine recommendations are restricted to provinces that border Brazil, Paraguay, and Bolivia. The goal of this paper is to describe the adverse events following immunization (AEFI) against YF in Argentina during the outbreak in the northeastern province of Misiones, which occurred from January 2008 to January 2009. During this time, a total of nine cases were reported, almost two million doses of vaccine were administered, and a total of 165 AEFI were reported from different provinces. Case study analyses were performed using two AEFI classifications. Forty-nine events were classified as related to the YF vaccine (24 serious and 1 fatal case), and 12 events were classified as inconclusive. As the use of the YF 17D vaccine can be a challenge to health systems of countries with different endemicity patterns, a careful clinical and epidemiological evaluation should be performed before its prescription to minimize serious adverse events.